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COVID-19 and cancer registries: learning from the first peak
of the SARS-CoV-2 pandemic
Alvin J. X. Lee 1 and Karin Purshouse 2
The SARS-Cov-2 pandemic in 2020 has caused oncology teams around the world to adapt their practice in the aim of protecting
patients. Early evidence from China indicated that patients with cancer, and particularly those who had recently received
chemotherapy or surgery, were at increased risk of adverse outcomes following SARS-Cov-2 infection. Many registries of cancer
patients infected with SARS-Cov-2 emerged during the first wave. We collate the evidence from these national and international
studies and focus on the risk factors for patients with solid cancers and the contribution of systemic anti-cancer treatments (SACT—
chemotherapy, immunotherapy, targeted and hormone therapy) to outcomes following SARS-Cov-2 infection. Patients with cancer
infected with SARS-Cov-2 have a higher probability of death compared with patients without cancer. Common risk factors for
mortality following COVID-19 include age, male sex, smoking history, number of comorbidities and poor performance status.
Oncological features that may predict for worse outcomes include tumour stage, disease trajectory and lung cancer. Most studies
did not identify an association between SACT and adverse outcomes. Recent data suggest that the timing of receipt of SACT may
be associated with risk of mortality. Ongoing recruitment to these registries will enable us to provide evidence-based care.
British Journal of Cancer https://doi.org/10.1038/s41416-021-01324-x
BACKGROUND
Since the SARS-Cov-2 pandemic began at the start of 2020, cancer
teams around the world have adapted their practice in the aim of
protecting patients. After a period where restrictions were eased,
many countries have returned to national lockdowns as case
numbers rise. The challenge of protecting patients with cancer in a
world where SARS-Cov-2 is endemic has become all the more
apparent. During the first international phase of the SARS-Cov-2
pandemic, cancer services were paused as it was feared that
patients with cancer were at particular risk of severe infection. The
immunomodulatory effect of both cancer and many systemic anti-
cancer treatments (SACT) was identified as a risk factor for this
group, particularly given the evidence from previous infection
outbreaks.1–3 This was supported by early evidence from Wuhan
province, China, that cancer patients, and particularly those who
had recently received chemotherapy or surgery, were at increased
risk.4,5 Cancer treatment (including SACT and radiotherapy) and
care inherently requires physical contact and can result in side
effects, thereby further increasing the risk to patients. Many
countries adopted ‘shielding’ policies, advising patients to stay at
home.6 Remote consultations and rationalisation of treatment
modalities were introduced to minimise the risks for patients
requiring active treatment. Cancer services were also reorganised
to allow clinical services to prioritise the high clinical acuity of
COVID-19 patients, including redeploying staff to other clinical
areas. Overall, cancer teams and their patients made huge
adaptations in the face of significant uncertainty.3,7,8
As further waves of SARS-Cov-2 take hold, cancer teams around
the world must make decisions about how to move forward. There
is significant concern that delays to both cancer diagnosis and
treatment will lead to the mortality from cancer exceeding that
from SARS-Cov-2.7,9,10 Further, the backlog of patients for whom
diagnosis and treatment were delayed during the first wave will
see an increasing need for all forms of cancer treatment, and likely
at a more advanced cancer stage. Understanding which treatment
modalities confer the highest risk is vital in order to discuss the
relative risks with patients and facilitate collaborative decision-
making.
Cancer registries of patients infected with SARS-Cov-2 emerged
during the first wave to address these uncertainties, and to date
they likely offer the most comprehensive clinical data to guide
cancer teams. These have ranged from local or regional databases
to national and international registries. In this review, we aim to
collate the evidence from large national and international
registries and highlight trends and challenges these data present.
Fig. 1 illustrates the timeline of establishment of major COVID-19
and cancer registries, and significant COVID-19 and cancer
events. Overall, these studies suggest that patients with cancer
who develop SARS-Cov-2 have a higher probability of death
compared with patients without cancer. Common risk factors for
mortality following SARS-Cov-2 infection identified in patients
with cancer include age, male sex, smoking history, the number of
comorbidities and poor performance status (PS). Oncological
features that may predict for worse outcomes include tumour
stage and progressive disease, and possibly lung cancer.
Evidence for the safety of SACT is more conflicting with most
studies identifying no association with adverse outcomes, while
others report that in some groups, chemotherapy or immunother-
apy may confer an increased risk. Recent data have suggested
that timing of receipt of SACT in relation to SARS-Cov-2
diagnosis may affect outcomes following SARS-Cov-2 infection.11
A key challenge underlying any comparisons lie in the diversity
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between these registries and the populations they describe,
noting that the population of cancer patients actively treated
during the first wave of SARS-Cov-2 may not reflect the overall
cancer population.
METHODS
A search of the PubMed database, and European Society for
Medical Oncology (ESMO) and American Society of Clinical
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Fig. 1 Timeline of establishment of COVID-19 and cancer registries, and significant COVID-19 and cancer events. Figure created with
BioRender.com.
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up to October 14, 2020. Keywords used were “COVID-19”,
“SARS-Cov-2”, “cancer”, “malignancy”. Registries that were
described as national or multinational were included. We note
that other registries have been established and have not yet
published their findings, such as the ESMO-CoCARE Registry12 and
NCI COVID-19 in Cancer Patients Study (NCCAPS)13 and these
studies have been excluded from the review. Table 1 summarises
the published output from the registries identified, which are
explored in more detail below.
COVID-19 AND CANCER REGISTRIES
CCC-19
The Clinical impact of COVID-19 on patients with Cancer (CCC-19)
cohort study included adult patients with active or previous
cancer with a serological confirmation of SARS-Cov-2 infection in
patients from over 120 institutions across the USA, Canada and
Spain. The first analysis of 928 patients showed 39% were on
active anti-cancer treatment, and only 43% had active (measur-
able) cancer. The mortality rate was 13%, and after logistic
regression analysis, age, male gender, smoking, comorbidities >2,
active cancer and ECOG PS > 2 were associated with increased
30-day mortality. Neither cancer type nor recent anti-cancer
therapy or surgery were associated with increased mortality.14 This
is the lowest mortality rate seen in any cancer registry study and
perhaps reflects a higher SARS-Cov-2 testing strategy, compared
with many European countries where testing was initially only on
a symptomatic basis.
The most recent analysis from CCC-19 of 4169 patients
identified male gender, age, smoking, multiple comorbidities
(>2), ECOG PS > 0, progressive cancer, haematological or other
concurrent solid-organ cancer and severe presenting illness with
COVID-19 with worse outcomes.15 A simultaneous analysis of 3920
patients identified the highest mortality was seen in patients who
had received treatment in the previous 1–3 months. Standardised
incidence ratios were highest in those who had received chemo-
or chemoimmunotherapy within 2 weeks of SARS-Cov-2 infection.
It is notable that haematology patients made up 26% of this
cohort, given the finding from the UK registry of a higher mortality
rate in this group.11,16 This is particularly as an increased mortality
rate in targeted treatments appears to be driven by anti-CD20
agents such as rituximab which are used almost exclusively in
haematological malignancies.
ISARIC—clinical characterisation protocol (CCP)-cancer UK
The International Severe Acute Respiratory and Emerging Infec-
tions Consortium (ISARIC)-4C COVID-19 Clinical Information Net-
work (CO-CIN) is a UK-wide collaborative collecting data on
hospital in-patients with confirmed or clinically likely SARS-Cov-2
infection. Data on 20,133 patients hospitalised due to SARS-Cov-2
suggested cancer was a factor associated with mortality.17 In their
first cancer-specific analysis presented at the ESMO 2020 congress,
1797 (8.6%) of participants had malignant neoplasm, with 35%
discharged alive, and a mortality rate of 35%. With updated data
presented at ESMO, cancer was identified as a risk factor for death
in all age groups, with a mortality rate of 40.5%.18 It is notable that
the definition of cancer does not describe whether cancers are
historical or active, solid organ or haematological, or the cancer
stage or status of cancer treatment. All patients in this cohort were
hospitalised patients and therefore likely had a more severe SARS-
Cov-2 disease than other registries.
OnCOVID
The OnCovid study reported on 890 patients from the UK, Spain,
Italy and Germany. They included patients with current and
previous cancer – 62.5% were defined as having ‘active
malignancy’.19 Just over half (53.8%) of the whole cohort had
received SACT in the previous 4 weeks. They reported a mortality
rate of 33.6%, comparable with those from other European patient
cohorts, and similarly identified age, male gender and more than
two comorbidities as risk factors. Interestingly, while they also
reported no negative survival impact of SACT overall, they also
identified that SACT was associated with better outcomes (HR
0.71, 95% CI 0.53–0.95; P= 0.019) but noted that this cohort had a
greater proportion of young, female and less comorbid patients.
TERAVOLT
This cohort is composed solely of thoracic cancers, including small
and non-small cell lung cancers and rarer subtypes such as
pulmonary neuroendocrine neoplasms. In their preliminary find-
ings, they identified that 76% of patients were hospitalised and
33% died. Multivariate analysis only identified smoking history as a
risk factor for death.20 An update presented at the ESMO 2020
congress of 1012 patients from 20 countries identified age (>65),
cancer stage (stage > III), current smoker status and steroids prior
to SARS-Cov-2 infection confirmation as risk factors for death after
multivariate analysis. Neither chemotherapy nor tyrosine kinase
inhibitors (TKIs) were associated with increased mortality, and this
analysis identified a reduced risk for mortality for patients on
immunotherapy.21 In the TERAVOLT cohort, the majority of
patients were on active cancer treatment (74% in the first analysis,
65% in the second), the highest of all the SARS-Cov-2 cancer
registries. Despite this, the mortality rate was not notably higher.
UKCCMP
This UK-wide registry included patients from over 70 centres
across the UK and reported on 800 patients with cancer treated
within the last 12 months or metastatic cancer. The overall
mortality rate was 28% in a population of symptomatic patients
seen in secondary care. This early analysis highlighted a similar
proportion of patients on active treatment as TERAVOLT (76% in
the last 4 weeks prior to SARS-Cov-2 confirmation) and identified
age, male gender and comorbidities as risk factors for mortality.
Similar to other registries reporting at this time, recent
chemotherapy was not associated with a worse mortality rate
after multivariate analysis.22 A subsequent analysis compared the
UKCCMP cohort with a non-SARS-Cov-2 cancer cohort via the UK
Office of National Statistics (ONS). A relative over-representation of
haematological malignancies in the UKCCMP cohort suggested
this group may be more vulnerable to SARS-Cov-2 infection.
Further multivariate analysis highlighted a higher mortality rate
with recent chemotherapy in this group.16
Dutch oncology COVID-19 consortium (DOCC)
This study of solid organ and haematological malignancies
evaluated 351 patients with serological or radiological evidence
of SARS-Cov-2 infection. The overall mortality rate was 32.3%, with
age >65 years, male gender, previous/other cancer, and active
haematological or lung cancer identified as risk factors of death
after multivariate analysis. Recent treatment (<30 days) had no
bearing on outcome.23
SAKK 80/20 CaSA
A registry of 357 patients from 23 Swiss centres was presented at
the ESMO 2020 congress. 57% of patients had received anti-
cancer treatment within 3 months of their diagnosis of SARS-Cov-
2. They observed a mortality rate of 18%, and identified age and
treatment with palliative intent as being associated with worse
outcomes—full analysis is awaited.24
GCO-002 CACOVID-19
In this French nationwide multicentre study of cancer and SARS-
Cov-2, patients were included if they had cancer and excluded for
those treated curatively more than 5 years ago with no evidence
of recurrent disease.25 Analysis of 1289 patients again highlighted
male gender and PS > 2 as being associated with death, in
COVID-19 and cancer registries: learning from the first peak of the. . .
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addition to the updated Charlson comorbidity index (uCCI) and
admission to ICU. A thoracic primary tumour and corticosteroids
prior to SARS-Cov-2 diagnosis were associated with increased
SARS-Cov-2 severity, defined as admission to ICU and/or mechan-
ical ventilation and/or death. Multivariate analysis suggested no
association between cytotoxic chemotherapy within 3 months (OR
1.32, 95% CI 0.92–1.89; P= 0.13), however this became significant
when only PCR-confirmed SARS-Cov-2 patients (n= 952) were
considered (OR 1.53, 95% CI 1.00–2.34; P= 0.05). Given that this
result is at the limit of significance, this result should be
considered alongside the other studies described here which
more comprehensively contrast with this finding. This could be a
result of reporting bias, which the authors themselves propose in
their discussion.25
DISCUSSION
Do patients with cancer do worse?
Overall, there is a growing body of evidence that patients with a
history of cancer appear to have a higher mortality rate compared
with those without cancer. These large national and international
studies demonstrate that the mortality rate of patients with cancer
who are infected with SARS-Cov-2 ranges between 13 and 40.5%.
Most of these studies did not have a direct comparator arm with
patients without cancer. However, ISARIC shows that within the
cohort, patients with cancer had poorer outcomes with a 40.5%
risk of mortality in those with cancer compared with 28.5% in
those without cancer (HR 1.62, 95% CI 1.56–1.68; P < 0.001).17,18
Additionally, there have been several published studies, the
majority of them within single healthcare systems from Europe,
China and the USA, that have also demonstrated that a history of
solid tumours is an independent risk factor for mortality when
compared with patients without cancer.26–31 Only one, a European
analysis of SARS-Cov-2-infected patients with (n= 435) and
without (n= 2636) cancer, showed no relationship between
cancer and SARS-Cov-2 outcome once age, gender and comor-
bidities were accounted for.32 They did note that patients with
cancer were more likely to be older and with pre-existing
conditions. This outlier result may be due to differences in the
way in which cases were identified. The weight of evidence
favours cancer as an independent risk factor, noting that cancer is
itself associated with other SARS-Cov-2-related risk factors such as
increasing age and certain comorbidities.
Cancer, even within solid cancers, comprises a collection of very
heterogeneous diseases with different outlooks and treatments.
Each registry had a different definition of cancer, with some likely
including patients for whom a cancer diagnosis in the past may no
longer be relevant. Can we therefore define the characteristics of
patients with cancer who have increased risks of worse outcomes
following SARS-Cov-2 infection?
What characteristics of patients with cancer predispose to
increased risk from SARS-Cov-2?
Common risk factors for poorer outcomes following SARS-Cov-2
infection in patients with cancer include age, male sex, a history of
smoking, increasing number of comorbidities, prior steroid use,
and performance status. Cardiovascular comorbidities are also
associated with poorer outcomes. These risk factors are similar to
that of the general population who acquire COVID-19.33,34
What cancer-specific characteristics increase the risk of mortality
from SARS-Cov-2?
Tumour type. Haematological cancers have been associated with
worse outcomes following SARS-Cov-2 infection.16,23 Focusing on
solid tumours, thoracic cancers were initially identified as being
associated with worse outcomes. The TERAVOLT study suggested
a higher mortality rate for thoracic malignancies; however, this
was when compared with contemporaneous published studies as
the study did not directly compare with other solid cancer types.20
Results from the recently presented GCO-002 CACOVID-19 at the
ESMO Congress 2020 supports the findings of worse outcomes for
patients with thoracic cancers.35 However, other multinational and
national registries have not detected an association between
thoracic malignancies and increased risk of death, as seen in
Table 1. A study in a New York hospital system and a multicentre
study in China26,29 demonstrated that patients with lung cancer
had a higher risk of adverse outcomes when compared with other
cancer types (55% vs 28%, and 18.8% vs 11.1%, respectively).
Potential reasons for patients with thoracic tumours having worse
outcomes may include age, pre-existing lung comorbidities, a
history of smoking and potentially lower respiratory reserve due to
lung cancer or previous interventions including surgery and
radiotherapy. A multivariate analysis in the TERAVOLT study
demonstrated that chronic obstructive pulmonary disease (COPD),
hypertension, male sex, older age and a history of smoking were
risk factors for worse prognosis.20
Tumour stage or status. The OnCovid study did not demonstrate
an association between advanced cancer stage and outcomes.
However, active cancer compared with those in remission or with
no measurable disease was an independent risk factor for death
(HR 1.81, 95% CI 1.35–2.44; P < 0.0001).19 This association with
disease trajectory was also seen in the CCC-19 cohort. In the CCC-
19 study,14 disease which was stable or responding to treatment
was associated with increased risk of mortality compared with
patients who were in remission or had no evidence of disease with
an OR 1.79 (95% CI 1.09–2.95). Those with progressive disease
were found to have an even higher increased OR at 5.20 (95%
CI 2.77–9.77). In the updated analysis of 3887 patients from the
CCC-19 registry presented at the ESMO 2020 congress, progressive
cancer was shown again to be associated with increased risks for
mortality following SARS-Cov-2 infection with adjusted odds ratio
(aOR) for 30-day all-cause mortality of 2.9 (95% CI 2.1–4.0).15
A multicentre study in China26 comprising of 105 hospitalised
patients showed that metastatic disease (stage IV) was associated
with higher risks of death (OR 5.58, 95% CI 1.71–18.23; P= 0.01), ICU
admission (OR 6.59, 95% CI 2.32–18.72; P< 0.01), and use of invasive
mechanical ventilation (OR 55.42, 95% CI 13.21–232.47; P< 0.01).
Taken together, the data from larger studies indicate that the
trajectory of a patient’s cancer and how it is responding to treatment
may affect outcomes following SARS-Cov-2 more so than stage. The
mechanisms by which advancing disease or stage affect SARS-Cov-2
outcomes are yet to be demonstrated. Patient fitness which can be
negatively impacted due to progressive or metastatic cancer may be
a risk factor, and this is in keeping with poorer PS being a risk factor
for adverse outcomes (Table 1). Advanced or advancing disease is also
associated with chronic inflammation and T-cell dysfunction and
exhaustion which may also explain the poorer outcomes for these
patients.36
Systemic anti-cancer therapy (SACT). It was initially assumed that
SACT could lead to worse outcomes following SARS-Cov-2
infection, which was further supported by early data from a small
cohort of patients during the first wave.5 Chemotherapy generally
has an immunosuppressive effect. Patterns of SACT prescribing,
especially chemotherapy, were altered globally to try to reduce
this hypothetical risk to patients. The safety and feasibility of
delivering SACT remains an ongoing concern to patients and
oncologists.
SACT comprises many different treatment modalities including
chemotherapy, immunotherapy, targeted therapies, and hormone
therapies. There are many different drugs and drug combinations,
each with different mechanisms of action. Many studies have
grouped treatments to analyse the risks for poorer COVID-19
outcomes following SACT. It is unlikely that associations between
specific SACT regimens and COVID-19 outcomes will be seen
COVID-19 and cancer registries: learning from the first peak of the. . .
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without more targeted studies. Further, it is unlikely that patients
receiving SACT during the pandemic reflect the population of
cancer patients who would normally have been considered for
SACT before the pandemic. These caveats must be borne in mind
when interpreting registry data which, to date, is almost
exclusively based on data obtained during the first wave.
Initial data from these registries did not demonstrate an
association between SACT and mortality (Table 1). Recent evidence
has been more conflicting with regards to the risks between SACT
and mortality following SARS-Cov-2 infection. Changes in patient
selection for SACT and changes to more “COVID-19 safe” regimens
may also further confound matters. In the second OnCovid study,19
receipt of SACT was associated with better outcomes (HR 0.71, 95%
CI 0.53–0.95; P= 0.019). These findings may be explained by
patient selection and is likely to be associative rather than
causative as the cohort of patients receiving SACT in that study
were younger, less comorbid, and proportionally more female.
In the ISARIC study, active cancer treatment was associated with
increased mortality in those aged 50 and above with the risk of
mortality increasing with age. However, there was no further
information available on the types of malignancies nor information
on the active cancer treatments received.18 The second UKCCMP
analysis found that patients with haematological malignancies who
received SACT had an increased risk of mortality. However, no
association was found in patients with other tumour types
following SACT.16
The CCC-19 consortium presented data at the ESMO 2020
congress exploring the temporal association between SACT and
mortality. They categorised patients into those who received SACT <
2 weeks, 2–4 weeks, 1–3 months or 3–12 months before a diagnosis
of COVID-19. Receipt of chemotherapy or chemotherapy and
immunotherapy within 2 weeks of being diagnosed with SARS-
Cov-2 was associated with increased mortality (Table 1).11 Further
numbers of patients are needed to confirm this finding, especially as
the lower limits of the confidence interval for both groups
approached 1 and haematological patients comprised about a
quarter of the cohort. Interestingly, in the updated TERAVOLT study
presented at the ESMO 2020 congress, chemotherapy or no therapy
was associated with poorer outcomes when compared with patients
receiving immunotherapy, chemotherapy-immunotherapy or tar-
geted therapies.21 Patients who were not receiving treatments
appeared to have the worst outcomes. Performance status, stage of
disease, smoking history, prior steroid use and age were found to
have a larger effect on mortality. This indicates that patient selection
could be the reason why patients who were not receiving treatment
or patients on chemotherapy did worse when compared with other
treatment modalities, as these patients with lung cancer are usually
on later lines of anti-cancer treatment.
Radiotherapy. Radiotherapy services were similarly adjusted
during the first wave of the global pandemic. It is likely that the
risk posed by radiotherapy is primarily due to the in-person
contact required, sometimes daily over several weeks, rather than
radiotherapy itself. No study has identified an association between
recent radiotherapy and mortality, although the number of
patients on whom conclusions can be drawn remain surprisingly
small. For example, in TERAVOLT, only 13 thoracic cancer patients
of the 147 on active therapy were receiving radiotherapy (stand-
alone or in combination with SACT).20 In CCC-19 and UKCCMP, 12
and 76 patients respectively had recently had radiotherapy.14,22
Given the likely significant rise in radiotherapy given delays in
diagnosis, pausing of SACT and reduction in surgical capacity
during the first wave, an evidence-based strategy will be vital to
guide clinical teams and their patients. In the UK, the National
Cancer Research Institute’s Clinical and Translational Radiotherapy
(NCRI CTRad) has launched COVID RT to study the impact of SARS-
Cov-2 on radiotherapy and outcomes.37
CONCLUSIONS
The SARS-Cov-2 pandemic has had, and continues to have, an
impact on patients with cancer. Personalised, evidenced-based
oncological care is important to safeguard the wellbeing of
patients with cancer and to ensure that anti-cancer treatment can
continue as safely as possible to avoid compromising overall
outcomes. In this review, we have discussed the findings from key
large national and international studies which were established at
a short notice.
Overall, these studies suggest that patients with cancer are at
an increased risk of mortality following SARS-Cov-2 infection
compared with patients without cancer. Clinical factors such as
age, male sex, number of comorbidities, cardiopulmonary
comorbidities, smoking history, and performance status have all
been associated with worse outcomes in patients with cancer who
acquire SARS-Cov-2. Cancer-specific features that have been
identified as being associated with worse outcomes include
tumour stage and disease progression, with some studies
identifying thoracic cancers as being associated with increased
risk compared with other solid tumours. The majority of the
studies discussed did not demonstrate an association between
SACT and worse outcomes. However, recent data suggest that
timing of treatment in relation to acquisition of COVID-19 may be
significant with receipt of chemotherapy and chemotherapy-
immunotherapy within 2 weeks associated with worse outcomes.
This may be useful in advising patients about shielding in a
treatment-specific manner. Larger studies with more patient
numbers are needed to confirm these findings especially with
regards to timing of SACT and patient outcomes.
The cancer community responded rapidly to develop these
multicentre registries and they are highly heterogeneous in their
definitions. Consequently, comparisons are difficult, and they must
be interpreted with the cautions outlined above. Nonetheless, they
have contributed immensely to our understanding of the risks to
patients with cancer following SARS-Cov-2 infection during the first
peak of the pandemic. Ongoing recruitment to such registries will
help our evolving understanding regarding the interaction of SARS-
Cov-2 and cancer, including timing of SACT, safety of individual
SACT regimens and SACT in specific tumour types.
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